Co-delivery of doxorubicin and paclitaxel by PEG-polypeptide nanovehicle for the treatment of non-small cell lung cancer

doi:10.1016/j.biomaterials.2014.04.034

CORC > 化学研究所 > 中国科学院化学研究所

	Co-delivery of doxorubicin and paclitaxel by PEG-polypeptide nanovehicle for the treatment of non-small cell lung cancer
	Lv, Shixian 1,5; Tang, Zhaohui 1; Li, Mingqiang 1,5; Lin, Jian 1,5; Song, Wantong 1; Liu, Huaiyu 3; Huang, Yubin 4; Zhang, Yuanyuan 2; Chen, Xuesi 1
刊名	BIOMATERIALS
	2014-07-01
卷号	35 期号:23 页码:6118-6129
关键词	Chemotherapy Drug Co-delivery Nanoparticle Polypeptide Controlled Drug Release
ISSN号	0142-9612
DOI	10.1016/j.biomaterials.2014.04.034
英文摘要	Despite progress, combination therapy of different functional drugs to increase the efficiency of anticancer treatment still remains challenges. An amphiphilic methoxy poly(ethylene glycol)-b-poly(L-glutamic acid)-b-poly(L-lysine) triblock copolymer decorated with deoxycholate (mPEsG-b-PLG-b-PLL/DOCA) was synthesized and developed as a nanovehicle for the co-delivery of anticancer drugs: doxorubicin (DOX) and paclitaxel (PTX). The amphiphilic copolymer spontaneously self-assembled into micellar-type nanoparticles in aqueous solutions and the blank nanoparticles possessed excellent stability. Three different domains of the copolymer performed distinct functions: PEG outer corona provided prolonged circulation, middle biodegradable and hydrophilic PLG shell was designed for DOX loading through electrostatic interactions, and hydrophobic deoxycholate modified PLL served as the container for FIX. In vitro cytotoxicity assays against A549 human lung adenocarcinoma cell line demonstrated that the DOX + PTX co-delivered nanoparticles (Co-NPs) exhibited synergistic effect in inducing cancer cell apoptosis. Ex vivo DOX fluorescence imaging revealed that Co-NPs had highly efficient targeting and accumulation at the implanted site of A549 xenograft tumor in vivo. Co-NPs exhibited significantly higher antitumor efficiency in reducing tumor size compared to free drug combination or single drug-loaded nanoparticles, while no obvious side effects were observed during the treatment, indicating this co-delivery system with different functional antitumor drugs provides the clinical potential in cancer therapy. (C) 2014 Elsevier Ltd. All rights reserved.
语种	英语
出版者	ELSEVIER SCI LTD
WOS记录号	WOS:000337212200014
内容类型	期刊论文
源URL	[http://ir.iccas.ac.cn/handle/121111/51893]
专题	中国科学院化学研究所
通讯作者	Chen, Xuesi
作者单位	1.Chinese Acad Sci, Changchun Inst Appl Chem, Key Lab Polymer Ecomat, Changchun 130022, Peoples R China 2.Wake Forest Univ, Bowman Gray Sch Med, Wake Forest Inst Regenerat Med, Winston Salem, NC 27157 USA 3.Jilin Univ, Lab Anim Ctr, Changchun 130012, Peoples R China 4.Chinese Acad Sci, Changchun Inst Appl Chem, State Key Lab Polymer Phys & Chem, Changchun 130022, Peoples R China 5.Univ Chinese Acad Sci, Beijing 100039, Peoples R China
推荐引用方式 GB/T 7714	Lv, Shixian,Tang, Zhaohui,Li, Mingqiang,et al. Co-delivery of doxorubicin and paclitaxel by PEG-polypeptide nanovehicle for the treatment of non-small cell lung cancer[J]. BIOMATERIALS,2014,35(23):6118-6129.
APA	Lv, Shixian.,Tang, Zhaohui.,Li, Mingqiang.,Lin, Jian.,Song, Wantong.,...&Chen, Xuesi.(2014).Co-delivery of doxorubicin and paclitaxel by PEG-polypeptide nanovehicle for the treatment of non-small cell lung cancer.BIOMATERIALS,35(23),6118-6129.
MLA	Lv, Shixian,et al."Co-delivery of doxorubicin and paclitaxel by PEG-polypeptide nanovehicle for the treatment of non-small cell lung cancer".BIOMATERIALS 35.23(2014):6118-6129.